Concord Biotech · NSE: CONCORDBIO · BSE: 543960

Q1 FY27 results · Apr–Jun 2026

Concord Biotech reported revenue from operations of ₹257.49 crore (up 26.2% from Q1 FY26) and net profit of ₹57.70 crore (up 31.0% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	257.49	203.99	+26.2%	326.08	−21.0%
Other income	12.83	13.68	−6.2%	15.35	−16.4%
Total income	270.31	217.67	+24.2%	341.43	−20.8%
Profit before share of associates & JVs and tax	77.07	57.24	+34.6%	114.25	−32.5%
Share of profit/(loss) of associates & JVs	1.28	1.49		(0.18)
Net profit for the period	57.70	44.06	+31.0%	88.47	−34.8%
Attributable to shareholders of the company	58.53	44.06	+32.8%	88.79	−34.1%
EPS, basic (₹)	5.52	4.21	+31.1%	8.46	−34.8%
Net margin (%)	22.4	21.6		27.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	260.52	203.99	+27.7%	325.89	−20.1%
Other income	13.10	13.68	−4.2%	15.54	−15.7%
Total income	273.61	217.67	+25.7%	341.43	−19.9%
Profit before tax	82.21	57.24	+43.6%	118.38	−30.6%
Net profit for the period	61.19	42.57	+43.8%	90.02	−32.0%
EPS, basic (₹)	5.85	4.07	+43.7%	8.60	−32.0%
Net margin (%)	23.5	20.9		27.6

Consolidated

Filed with BSE: 31 Jul 2026, 18:35 IST
Board meeting: 31 Jul 2026
Period: 01 Apr 2026 to 30 Jun 2026
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 31 Jul 2026, 18:35 IST
Board meeting: 31 Jul 2026
Period: 01 Apr 2026 to 30 Jun 2026
Review status: Unaudited
Source: XBRL filing on BSE